Evidence map›Paper›PMID 38284009›Full record

ArticleACS omega2024

Liposome Nanocarriers Based on γ Oryzanol: Preparation, Characterization, and

Ahmed J Jasim, Salim Albukhaty, Ghassan M Sulaiman, Hassan Al-Karagoly, Majid S Jabir, Ali M Abomughayedh, Hamdoon A Mohammed, Mosleh M Abomughaid

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ahmed J JasimDepartment of Biomedical Engineering, University of Technology, Baghdad 10066, Iraq.
Salim AlbukhatyDepartment of Chemistry, College of Science, University of Misan, Maysan 62001, Iraq.
Ghassan M SulaimanDivision of Biotechnology, Department of Applied Sciences, University of Technology, Baghdad 10066, Iraq.ORCID https://orcid.org/0000-0001-6388-3849
Hassan Al-KaragolyDepartment of Internal and Preventive Medicine, College of Veterinary Medicine, University of Al-Qadisiyah, Al-Diwaniyah 58001, Iraq.
Majid S JabirDivision of Biotechnology, Department of Applied Sciences, University of Technology, Baghdad 10066, Iraq.ORCID https://orcid.org/0000-0003-0759-8298
Ali M AbomughayedhPharmacy Department, Aseer Central Hospital, Ministry of Health, Asir 62523, Saudi Arabia.
Hamdoon A MohammedDepartment of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia.ORCID https://orcid.org/0000-0003-2896-6790
Mosleh M AbomughaidDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, 255, Al Nakhil, Bisha 67714, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to develop and characterize liposome nanocarriers based on γ oryzanol and evaluate their potential

Identifiers

PMID38284009
PMCPMC10809378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.